BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
申请人:Fukuda Yasumichi
公开号:US20140243302A1
公开(公告)日:2014-08-28
Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.
SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS
申请人:F. Hoffmann-La Roche AG
公开号:EP1869036B1
公开(公告)日:2010-11-03
US7304074B2
申请人:——
公开号:US7304074B2
公开(公告)日:2007-12-04
[EN] SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS<br/>[FR] 1,5-NAPHTYRIDINEAZOLIDINONES SUBSTITUÉES EN TANT QU'AGENTS INHIBITEURS DE CDK
申请人:HOFFMANN LA ROCHE
公开号:WO2006106046A1
公开(公告)日:2006-10-12
[EN] The present invention provides novel, substituted 1,5-naphthyridine azolinones of formula (I) which inhibit Cdkl and are selective against Cdk2 and Cdk4. These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful as anti-cancer agents. [FR] La présente invention concerne de nouvelles 1,5-naphtyridineazolidinones substituées de formule (I) qui inhibent CdkI et sont sélectives vis-à-vis de Cdk2 et Cdk4. Ces composés et leurs sels de qualité pharmaceutique présentent une activité antiproliférative et peuvent être employés en tant qu'agents anticancéreux.
Substituted 1,5-naphthyridine azolinones
申请人:Liu Jin-Jun
公开号:US20060223843A1
公开(公告)日:2006-10-05
Substituted 1,5-naphthyridine azolinones inhibit Cdk1 and are selective against Cdk2 and Cdk4. These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful as anti-cancer agents.